EU/3/03/161

Table of contents

About

On 2 October 2013, orphan designation (EU/3/03/131) was granted by the European Commission to Gene Signal SAS, France, for antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT) for the treamtne of neovascular glaucoma.

  • List item

    EU/3/03/161: Public summary of positive opinion for orphan designation of antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT) for treatment of neovascular glaucoma (PDF/142.24 KB)

    Adopted

    First published: 26/04/2004
    Last updated: 26/04/2004
    EMEA/COMP/1421/03

    • Key facts

    Active substance
    Antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT)
    Disease / condition
    Treatment of neovascular glaucoma
    Date of first decision
    02/10/2003
    Outcome
    Positive
    EU designation number
    EU/3/03/161

    Sponsor's contact details

    Gene Signal SAS
    France

    Patients' organisations

    For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

    • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

    • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

    How useful was this page?

    Add your rating